the adaapt tech is the key, they have just sold products of it.
But yes there was money put into development of these products and refining the manufacturing process.
Yes it is cheap, but the best deal you could expect for a company that was in such a poor state.
While they cant make products exactly the same as these, their are still other products that can be developed from the core tech.
Ann: CardioCel and VascuCel rights sold to LeMaitre Vascular, page-191
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |